<div id="readability-page-1"><p>Central Pacific Bank Trust Division raised its holdings in  Cencora, Inc. (NYSE:COR - Free Report) by 654.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,188 shares of the company's stock after purchasing an additional 3,633 shares during the quarter. Central Pacific Bank Trust Division's holdings in Cencora were worth $1,309,000 as of its most recent SEC filing.</p><ul><li>Top 3 S&amp;P 500 Winners in a Losing Market</li></ul><p>Other institutional investors and hedge funds also recently bought and sold shares of the company. Kovitz Investment Group Partners LLC lifted its position in  Cencora by 9.3% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 3,513 shares of the company's stock worth $977,000 after buying an additional 299 shares in the last quarter.  Ethic Inc. raised its stake in shares of  Cencora by 2.4% in the first quarter. Ethic Inc. now owns 9,769 shares of the company's stock worth $2,710,000 after acquiring an additional 233 shares during the last quarter.  Steward Partners Investment Advisory LLC raised its stake in shares of  Cencora by 1.0% in the first quarter. Steward Partners Investment Advisory LLC now owns 53,475 shares of the company's stock worth $14,871,000 after acquiring an additional 507 shares during the last quarter.  Aviso Financial Inc. lifted its position in shares of  Cencora by 17.5% during the first quarter. Aviso Financial Inc. now owns 8,769 shares of the company's stock worth $2,439,000 after purchasing an additional 1,305 shares in the last quarter.  Finally, Aptus Capital Advisors LLC grew its stake in shares of  Cencora by 39.7% during the first quarter. Aptus Capital Advisors LLC now owns 3,699 shares of the company's stock valued at $1,029,000 after purchasing an additional 1,052 shares during the last quarter. Institutional investors and hedge funds own  97.52% of the company's stock. </p><h2>Insider Activity</h2><p>In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer owned 65,746 shares in the company, valued at $24,105,113.44. The trade was a 7.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 15,290 shares of company stock valued at $5,012,227 in the last ninety days. 10.80% of the stock is owned by corporate insiders. </p><h2>Cencora Stock Up 1.3%</h2><ul><li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li></ul><p>Cencora stock opened at $350.33 on Tuesday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm has a market capitalization of $67.96 billion, a price-to-earnings ratio of 44.07, a PEG ratio of 1.64 and a beta of 0.63. The company's 50 day simple moving average is $344.19 and its 200 day simple moving average is $311.91. </p><p>Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the business posted $3.34 earnings per share. The business's revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS.  As a group, sell-side analysts anticipate that  Cencora, Inc. will post 15.37 EPS for the current year. </p><h2>Cencora Increases Dividend</h2><ul><li>Teva Pharma is the way to play the re-rise of generic drugs </li></ul><p>The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora's previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora's payout ratio is presently 30.19%. </p><h2>Analysts Set New Price Targets</h2><p>COR has been the subject of several research analyst reports. UBS Group boosted their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, November 7th. Evercore ISI  set a $400.00 target price on Cencora and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 10th. Weiss Ratings  reiterated a &#34;hold (c+)&#34; rating on shares of Cencora in a research report on Monday, December 8th. Finally, Wall Street Zen downgraded shares of Cencora from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, November 28th. One investment analyst  has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have assigned  a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $373.50.</p><p><b>Get Our Latest Research Report on Cencora</b></p><h2>Cencora Profile</h2> (Free Report)<p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cencora</li><li>What is MarketRank™? How to Use it</li><li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li><li>What Are the FAANG Stocks and Are They Good Investments?</li><li>Dell and HP Are Raising Prices—And Investors Should Take Note</li><li>3 REITs to Buy and Hold for the Long Term</li><li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cencora Right Now?</h2><p>Before you consider Cencora, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Central Pacific Bank Trust Division increased its holdings in Cencora, Inc. by 654.6% in the 3rd quarter, acquiring an additional 3,633 shares, now totaling 4,188 shares worth $1,309,000. Other institutional investors also increased their positions in Cencora. The company's stock opened at $350.33, with a market cap of $67.96 billion. Cencora reported $3.84 EPS for the quarter, surpassing estimates, and increased its quarterly dividend to $0.60 per share.</p>

Central Pacific Bank Trust Division Acquires 3,633 Shares of Cencora, Inc. $COR